Skip to main content

and
  1. No Access

    Article

    Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study

    Although early palliative care is recommended, resource limitations prevent its routine implementation. We report on the preliminary findings of a mixed methods study involving a randomized controlled trial (R...

    Camilla Zimmermann, Ashley Pope, Breffni Hannon in Supportive Care in Cancer (2023)

  2. Article

    Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

    Sanjay Popat, Myung-Ju Ahn, Simon Ekman, Natasha B. Leighl in Targeted Oncology (2023)

  3. No Access

    Article

    Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

    Central nervous system (CNS) metastases are common in non-small-cell lung cancer (NSCLC) and associated with poor prognosis and high disease burden. Effective options are needed to treat CNS metastases, and de...

    Sanjay Popat, Myung-Ju Ahn, Simon Ekman, Natasha B. Leighl in Targeted Oncology (2023)

  4. Article

    Open Access

    Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges

    In the current era of precision medicine, the identification of genomic alterations has revolutionised the management of patients with solid tumours. Recent advances in the detection and characterisation of ci...

    Miguel García-Pardo, Maisam Makarem, Janice J. N. Li in British Journal of Cancer (2022)

  5. Article

    Open Access

    Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial

    Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appr...

    Jeffrey S. Hoch, Annette Hay, Wanrudee Isaranuwatchai, Kednapa Thavorn in BMC Cancer (2019)

  6. Article

    Open Access

    Emerging therapies for non-small cell lung cancer

    Recent advances in the field of novel anticancer agents prolong patients’ survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing r...

    Chao Zhang, Natasha B. Leighl, Yi-Long Wu in Journal of Hematology & Oncology (2019)

  7. Article

    Open Access

    Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients

    We examined clinical outcomes in a population-based cohort of EGFR mutant advanced NSCLC patients, exploring the potential role of factors including tumour EGFR mutation fraction and cellularity in predicting out...

    Petra Martin, Carolyn J Shiau, Maria Pasic, Ming Tsao in British Journal of Cancer (2016)

  8. Article

    Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer

    Although women have an increased susceptibility to lung cancer, they also have a favorable clinical outcome. This may in part be due to female specific genetic and hormonal factors. In the present study, expre...

    Sri Navaratnam, Georgios Skliris, Gefei Qing, Shantanu Banerji in Hormones and Cancer (2012)

  9. No Access

    Article

    A Phase 2 study of perifosine in advanced or metastatic breast cancer

    First- and second-line chemotherapy with anthracyclines and taxanes in metastatic breast cancer yield a modest improvement in survival with potentially significant toxicity. Subsequent lines of chemotherapy yi...

    Natasha B. Leighl, Susan Dent, Mark Clemons in Breast Cancer Research and Treatment (2008)